ALA 5.41% 19.5¢ arovella therapeutics limited

Offer from the Company, page-119

  1. 5,759 Posts.
    lightbulb Created with Sketch. 809

    Not saying they didn’t have to resolve it, but Artimist has cost the company so much money and it’s got them no return. It’s not even ready to go to market 8 years later.

    Probably $8m- $10m spent, no return.
 
watchlist Created with Sketch. Add ALA (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.